Compare GSK plc (GSK) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares Core S&P 500 ETF — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while iShares Core S&P 500 ETF trades at $775.91. The key difference: GSK plc pays a 3.57% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | IVV | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $776.81 |
52-Week Low | $38.22 | $634.93 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
IVV, tracking the S&P 500, trades at $776.18, down 0.07% with a bullish technical outlook from moving averages but overbought RSI signals. Recent news highlights record highs and institutional activity, with JPMorgan raising its S&P 500 target to 8,000 amid strong earnings growth. The ETF shows resilience despite valuation concerns.
Outlook remains positive due to AI-driven earnings growth, but risks include high valuations and market volatility. Investors benefit from broad market exposure, yet should monitor inflation reports and geopolitical events that could trigger pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
